Skip 
Navigation Link
Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Frequent Blood Donations Safe for Some, But Not AllDrone Sets New Record for Transporting Blood SamplesGun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of Interest'Science Spin' Found Prevalent in Biomedical LiteratureHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening CompletionMany Americans Getting Medical Care They Don't NeedInsurer Aetna's Envelopes Revealed Customers' HIV StatusHealth Groups Demand 'R' Rating for Movies That Show SmokingGoogle Search for 'Depression' Now to Provide Screening TestPatients' Hearing Loss May Mean Poorer Medical CareFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?Steep Price Hikes Led to Drop in Use of 2 Heart Drugs at U.S. HospitalsAPA: Medical Discrimination Based on Size Stresses Patients2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryMedical Reality Catches Up to Science FictionFDA Looks to Reduce Nicotine in CigarettesAHA Hands-Only CPR Training Kiosks Available at More Airports$100 Sweetens the Pot for a ColonoscopyJust a Few Vaccine Refusers Could Endanger ManyASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: Study
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

High Costs for Myeloma Patients Not Getting Low-Income Subsidy


HealthDay News
Updated: May 31st 2017

new article illustration

WEDNESDAY, May 31, 2017 (HealthDay News) -- There is a substantial financial burden for Medicare beneficiaries with myeloma who do not receive a low-income subsidy (LIS) for orally-administered anticancer therapy, according to a study published online May 25 in the Journal of Clinical Oncology.

Adam J. Olszewski, M.D., from Rhode Island Hospital in Providence, and colleagues identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011. In multivariable models adjusted for sociodemographic and clinical characteristics, the authors analyzed the correlation between LIS and use of immunomodulatory drug (IMiD)-based therapy, delays between IMiD refills, and select health outcomes.

The researchers found that 41 percent of 3,038 beneficiaries received first-line IMiDs. For the first IMiD prescription, the median out-of-pocket cost was $3,178 and $3 for LIS nonrecipients and recipients, respectively; for the first year of therapy the corresponding median costs were $5,623 and $6. LIS receipt correlated with a 32 percent increased probability of receiving IMiDs among beneficiaries aged 75 to 84 years, and, in all groups, with a significantly lower risk of delays between refills (adjusted relative risk, 0.54). There was no significant difference in duration of therapy for LIS recipients and nonrecipients (median, 7.6 months). Significantly fewer emergency department visits and hospitalizations were seen for patients treated with IMiDs versus those receiving bortezomib without IMiDs.

"Medicare beneficiaries with myeloma who do not receive LISs face a substantial financial barrier to accessing orally administered anticancer therapy, warranting urgent attention from policymakers," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)